With apologies to Harry Kalas. Bexis had a couple of encounters with the “Wayback Machine” (a/k/a/ the “Internet Archive”) recently. If you don’t know| Drug & Device Law
For over fifty years, the BBC has been chronicling the exploits of that ultimate learned intermediary, Dr. Who. Over the decades, successive Doctors have| Drug & Device Law
Late last year, we discussed the dismissal of three purported California no-injury class actions alleging that certain over the counter (“OTC”) acne| Drug & Device Law
When a federal agency reverses course, the Supreme Court has a test to determine whether that agency action is impermissibly “arbitrary and| Drug & Device Law
Bexis has been updating the preemption chapter of his treatise on drug/device product liability litigation. He came across several preemption| Drug & Device Law
The plaintiff in Kane v. Covidien LP, 2025 U.S. Dist. Lexis 25718 (E.D.N.Y. Feb. 12, 2025), lost the bulk of her case recently, on a motion to dismiss no| Drug & Device Law
In 2018, our blogpost on In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices & Liability Litigation, 903 F.3d 278 (3d Cir.| Drug & Device Law
Researchers at Temple University here in Philly recently published a scientific article, “Learning Impairments, Memory Deficits, and Neuropathology in| Drug & Device Law
In addition to its recent revamp of its “§510(k)” substantial equivalence clearance process for medical devices, (see our post here), the FDA has also| Drug & Device Law
